GammaCan and Tel Ha'Shomer Scientists to Present Phase II Results of the GC 101 Melanoma Trial at the 5th International Congress
19 September 2006 - 9:30PM
Business Wire
GammaCan International, Inc. (OTCBB: GCAN) today announced that
physicians from Tel Ha'Shomer Hospital in Tel Aviv, and GammaCan
will present top line findings of the GC 101 trial at the 5th
Annual Congress on Autoimmunity taking place in Sorrento Italy from
November 29th through December 3rd, 2006. The presentation and
abstract are titled "Efficacy and Safety of IVIG Intravenous
Immunoglobulin in Patients with Metastatic Melanoma." The senior
authors are Drs. Jacob Schachter, MD and Uriel Katz, MD, PhD and
the study was fully funded by GammaCan International, Inc. The
researchers will present phase II clinical data examining the
efficacy and safety of IVIG (GCAN101) in treating malignant,
melanoma obtained from nine patients with metastatic disease who
had failed all other modalities of therapy. Top line results
suggest that IVIG may lead to stabilization of the disease in some
patients and that IVIG therapy in patients with advanced malignant
melanoma appears to be safe. Prof. Jacob Nusbacher, Director of
Medical & Scientific Affairs at GammaCan commented: "This study
is part of our larger GCAN 101 open label phase II study which also
includes prostate and colon cancer patients. Unlike most other
anti-cancer agents, IVIG has an excellent safety profile. Moreover,
the results we see in melanoma are encouraging, particularly when
one considers the advanced state of disease in the group of
patients that were treated. These results give us further impetus
to develop VitiGam, our next generation anti-melanoma
immunoglobulin therapy." Data from the colon and prostate cancer
arms will be published elsewhere. About GCAN101 GCAN101 (standard
IgG) is currently completing an open label, 30 patient phase II
trial designed to evaluate the efficacy and safety of IgG therapy
in cancer patients who failed all current therapies. The trial is
enrolling patients with colon cancer, melanoma and prostate cancer.
The colon and melanoma arms are fully enrolled. About GammaCan
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening
the patient's immune system. Many experts currently view
immunotherapy as a future alternative to today's standard
chemotherapy. GammaCan is developing VitiGam, its second generation
program. VitiGam is an IgG derived from the plasma of vitiligo
donors and is being developed to treat malignant melanoma. GammaCan
owns, and has applied for US patent protection covering the use of
IgG and vitiligo-derived IgG (VitiGam). For more information about
GammaCan visit www.GammaCan.com or call the company's headquarters
in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free
1-866-308-0396 (from North America). Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding the commercialization of an
anti-cancer immunotherapy and the Company developing the boosting
of cancer patients' immune systems with IgG into an effective
treatment. Actual outcomes and the Company's actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to finance
the planned development of the technology, unforeseen technical
difficulties in developing the technology, the inability to obtain
regulatory approval for human use, competitors' therapies proving
more effective, cheaper or otherwise preferable for consumers,
inability to market the product we produce, among other factors,
all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see
the risk factors associated with other early state medical research
and development companies filed with the SEC on Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024